Immutep (ASX:IMM), an Australian biotechnology company developing immunotherapy treatments for cancer and autoimmune diseases, has announced it will present more mature interim TACTI-002 clinical data at the 34th German Cancer Congress in Berlin later this month.
The company said the data relates to use of its lead product candidate eftilagimod alpha ('efti' or 'IMP321'), a soluble LAG-3 protein based on the LAG-3 immune control mechanism, as part of a combination treatment with MSD's immunotherapy KEYTRUDA (pembrolizumab).
The data will be presented as an abstract by the clinical trial's principal investigator, Dr Bernhard Doger, of START Madrid. The abstract was submitted as a late-breaking abstract.
The presentation is titled ‘Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab’.
The TACTI-002 trial is evaluating the combination of 'efti' with MSD’s KEYTRUDA in up to 109 patients with second-line head and neck squamous cell carcinoma or non-small cell lung cancer.